Martin Görner

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

R. Schlenk, M. Kieser, H. Serve, 2023, Trials.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

A. Jauch, Y. Ko, C. Scheid, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

U. Holtick, K. Kriegsmann, K. Movassaghi, 2023, Transfusion Medicine and Hemotherapy.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

E. Estey, R. Schlenk, R. Hills, 2017, Leukemia.

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

R. Schlenk, M. Schaich, C. Schliemann, 2024, Haematologica.

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

U. Holtick, K. Kriegsmann, K. Movassaghi, 2023, Transfusion Medicine and Hemotherapy.